Clinicopathologic features and prognosis of triple negative breast cancer

Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zhonghua yi xue za zhi 08/2009; 89(32):2261-4.
Source: PubMed


To analyze the clinicopathologic features and prognosis of triple negative breast cancer.
The clinical datas of 477 patients of primary breast cancer which were diagnosed by pathology in the 4th Hospital of Hebei Medical University from Jan. 2004 to Dec. 2004 were analyzed. All of the patients were divided into two groups according to the results of immunohistochemistry: one was triple negative breast cancer (TNBC) which included estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor (HER2) negative and other was non-triple negative breast cancer. We compared TNBC with the group of non-triple negative breast cancer in the clinicopathologic features. The disease-free survival (DFS) and overall survival (OS) were analyzed by Kaplan-Meier method.
Of the 477 patients, 12.6% (60/477) was TNBC patients in which 76.7% of age was younger than fifty years(46/60), 28.3% of T > 5 cm (17/60), 68.3% of lymph nodes metastasis (41/60), 31.7% of grade III (19/60) and 13.3% of family history of breast cancer (8/60), (P < 0. 05). Till June 2008, the median time of follow-up was 48 months (42-54 months). Local recurrence or distant metastasis were 26.7% (16/60) of TNBC which was higher than 15.3% (64/417) of non-triple negative cases; DFS was 68.3% in TNBC group and 79.6% in the non-triple negative breast cancer group. The OS was 81.7% in TNBC group and 90.9% in the non-triple negative breast cancer group (Log-Rank = 3.917, P = 0.048; Log-Rank = 4.838, P = 0.028).
These patients of triple negative breast carcinoma were usually young (age < 50), with tumor growth fast, much more invasion and poorly prognosis.

7 Reads
  • Source
    • "Combination index (CI) analysis is one of the most popular methods for evaluating drug interactions in combination cancer chemotherapy (Zhou et al., 2009). To evaluate the interaction between ATO, U0126 and LY29004, the combination index ( "
    [Show abstract] [Hide abstract]
    ABSTRACT: PI3K/Akt and MAPK/ERK pathways are differentially activated in neuroblastoma (NB) cell types. In an effort to enhance the effectiveness of the NB treatment, we designed experiments to evaluate the effects of ATO in combination with PI3K and MEK1/2 specific inhibitors, LY29004 and U0126, respectively, in SK-N-MC and SK-N-BE(2) cell lines. The results indicated that specific inhibition of PI3K and MEK1/2 significantly enhanced antiproliferative and proapoptotic effects of ATO in SK-N-BE(2), but not in SK-N-MC. Furthermore, In SK-N-BE(2), NF-κB activation was significantly suppressed by LY29004+ATO treatments as compared with ATO alone, indicating that inhibition of PI3K may enhance anti-neoplastic properties of ATO in I-type NB cells through suppression of NF-κB. Moreover, expression of c-Myc, Bad, Bax and ATM in SK-N-BE(2) cell line were significantly increased by U0126+ATO treatment as compared to treatment with ATO alone. Expression of telomerase hTERT was almost depleted by U0126+ATO treatment. Regarding the fact that activation of PI3K and MAPK in SK-N-BE(2) is higher than in other NB subtypes, we hypothesize that growth of SK-N-BE(2) cell line is highly dependent on these pathways and inhibition of these pathways may has promise for the treatment of multi-drug resistant I-type NB cells by ATO. However, for successful strategies for the treatment of this heterogeneous tumor, other combinations approaches need to be considered to simultaneously target other NB cells.
    Neurochemistry International 10/2013; 63(8). DOI:10.1016/j.neuint.2013.10.005 · 3.09 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: B-cell lymphoma (bcl)-2 is an anti-apoptotic gene, and it is a poor prognostic factor in various malignant tumors. However, the prognostic significance of bcl-2 expression in breast cancer remains controversial. We investigated the prognostic significance of bcl-2 according to cancer molecular subtype. Methods: We analyzed 411 patients with primary invasive breast cancer who underwent surgery at our institution between 1999 and 2001. The subtypes were classified as luminal (estrogen receptor [ER]+ and/or progesterone receptor [PR]+, irrespective of human epidermal factor receptor 2 [HER2]), triple-negative (ER-, PR-, and HER2-), or HER2 (ER-,PR-, and HER2+). Results: A total of 236 (57.4%) cases were positive for bcl-2, and bcl-2 expression was significantly associated with earlier stage, lower grade, expression of hormone receptor positivity, and HER2 negativity. No difference in disease-free survival (DFS) was observed based on bcl-2 expression. However, the prognostic significance of bcl-2 varied with subtype; bcl-2 was not a prognosticator in patients with the luminal and HER2 subtypes. However, patients with bcl-2(+) tumors of the triple-negative subtype showed significantly worse DFS than those with bcl-2(-) tumors (p=0.048). In a multivariate analysis, bcl-2 expression remained a significant predictor of recurrence in patients with the triple-negative subtype (hazard ratio, 3.26; 95% confidence interval, 1.40-7.59; p=0.006). Conclusion: The prognostic significance of bcl-2 varied with molecular subtype; bcl-2 expression was a poor prognosticator in patients with the triple-negative subtype, but not in those with the luminal and HER2 subtypes.
    Journal of Breast Cancer 02/2011; 14(Suppl 1):S10. DOI:10.4048/jbc.2011.14.S.S10 · 1.58 Impact Factor